Suppression of vincristine-mediated cytotoxic activity by mitoxantrone in human cell lines

Anticancer Research

Volumn 16, Issue 5 A, 1996, Pages 2645-2651

  Ho, Chi Kuan ^a   Au, Lo Chun ^a   Wang, Sheng Yuan ^a  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

Author keywords

Antagonist; Mitoxantrone; Vincristine

Indexed keywords

DNA FRAGMENT; MITOXANTRONE; TUBULIN; VINCRISTINE;

ARTICLE; CELL CULTURE; CELL CYCLE G2 PHASE; CELL DEATH; CELL LINE; CONTROLLED STUDY; CYTOTOXICITY; DRUG ACCUMULATION; DRUG ANTAGONISM; DRUG EFFECT; FLOW CYTOMETRY; GENE EXPRESSION; HUMAN; HUMAN CELL; MICROTUBULE ASSEMBLY; MITOSIS INHIBITION; ONCOGENE C MYC; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CELL CYCLE; DNA FRAGMENTATION; DNA, NEOPLASM; GENES, MYC; HUMANS; MITOXANTRONE; RNA, MESSENGER; THYMIDINE; TUBULIN; TUMOR CELLS, CULTURED; TUMOR STEM CELL ASSAY; URIDINE; VINCRISTINE;

EID: 0029858981     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. DeVita VT: The relationship between tumor mass and resistance to chemotherapy. Cancer(Phila.) 51: 1209-1220, 1983.
2. Goldie JH and Coldman AJ: The genetic origin of drug resistance in neoplasms: implication for systemic therapy. Cancer Res 44: 3648-3643, 1984.
3. Goldie JH and Coldman AJ: Quantitative model for multiple levels of drug resistance in clinical tumors. Cancer Treat Rep 67: 923-931, 1983.
4. Double JA and Bibby MC: Therapeutic index: A vital component in selection of anticancer agents for clincal trial. J Nat Cancer Inst 81(13): 988-994, 1989.
5. Bender RA and Chabner BA: Tubulin binding agents. In: Pharmacologic principles of cancer traetment. Chabner BA (Ed). W.B. Saunders. Philadelphia 1982, pp 256-268.
6. Nelson EM, Tewey KM and Liu LF: Mechanism of antitumor drug action: poisoning of marnmalian DNA topoisomerase II on DNA by 4′-(9acridinylamino)-methanesulfon-m-anisidide. Proc Natl Acad Sci USA 81: 1361-1365, 1984.
7. Tewey KM, Rowe TC, Yang L, Halligan BD and Liu LF: Adriamycininduced DNA damage mediated by mammalian DNA topoisomerase II. Science 226: 460-468, 1984.
8. Ho CK, Law SL, Chiang H, Hsu ML, Wang CC and Wang SY: Inhibition of microtubule assembly is a possible mechanism of action of mitoxanrone. Biochem Biophys Res Commun 180(I): 118-123, 1991.
9. Fidler TM, Dejoy SQ and Gibbons JJ: Selective immunomodulation by the antineoplastic agent mitoxantrone. I. Suppression of B lymphocyte function. J Immunol 137: 727-732, 1986.
10. Fidler TM, Dejoy SQ, Smith FR, et al: Selective immunomodulation by the antineoplastic agent mitoxantrone. II. Non-specific adherence suppressor cell derived from mitoxantrone treated mice. J Immunol 136: 2747-2754, 1986.
11. Frank P and Novak RF: Effects of mitoxantrone and bisanthrene on platelet aggregation and prostaglandin, thromboxane biosynthesis in vitro. Anticancer Res 6: 941-948, 1986.
12. Shackney SE and Ritchm PS: Cell kinetics. In: Pharmacologic principles of cancer treatment. Chabner BA (Ed). W.B. Saunders, Philadelphia 1982, pp 45-76.
13. Durr FE: Biologic and biochemical effects of mitoxantrone. Semin Oncol 11(3): 3-10, 1984.
14. Paciucci PA, Cuttner J and Holland JF: Mitoxantrone as single agent and combination chemotherapy in patients with refractory acute leukimia. Semin Oncol 11(3S1): 36-40, 1984.
15. Lenk H, Muller U and Tanneberger S: Mitoxantrone: mechanism of action, antitumor activity, pharmacokinetics, efficacy in the treatment of solid tumors and lymphomas, and toxicity. Anticancer Res 7: 1257-1264, 1987.
16. Van Belle SJP, de Planque MM, Smith IE, van Oosterom AT, Schoemaker TJ, Deneve W and McVie JG: Pharmacokinetics of mitoxantrone in humans following single-agent infusion or intraarterial injection therapy or combined-agent infusion therapy. Cancer Chemother Pharmacol 18: 27-32, 1986.
17. Ho CK, Chiang H, Li SY, Yuan CC, Ng HT: Establishment and characterization of a tumorigenic trophoblast-like cell line from a human placenta. Cancer Res 47: 3220-3224, 1987.
18. Ho CK, Wang CC, Li SY, Chiang H, Yu KJ, Wang SY: Characterization of a human tumorigenic poorly differentiated trophoblast cell line. In Vitro Cell Dev Biol 30A: 415-417, 1994.
19. Mang LL, Ping KH, San CY. Establishment and characterization of a new human breast carcinoma cell line. J Chinese Oncol Sol 1: 27-30, 1985.
20. Mossman T: Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Meths 65: 55, 1983.
21. Kuriyama R, Sakai H: Viscometric demonstration of tubulin polymerization. J Biochem 75: 463-471, 1974.
22. Sarih M, Souvannavong V, Adam A: Nitric oxide synthetase induces macrophage death by apoptosis. Biochem Biophys Res Commun 191: 503-508, 1993.
23. Chomczynski P, Sacchi N: Single step method of RNA isolation by acid guanidinium-thiocyanate-phenol-chloroform extraction. Analyt Biochem 162: 156-159, 1987.
24. Kolata G: Why do cancer cells resist drugs? Science 231: 220-221, 1986.
25. Shackney SE, Ritchm PS. Cell kinetics: In: Pharmacologic principles of cancer treatment. Chabner BA (Ed). W.B. Saunders, Philadelphia 45-76, 1982.
26. Durr FE: Biologic and biochemical effects of mitoxantrone. Semin Oncol 11(3): 3-10, 1984.
27. Paciucci PA, Cuttner J, Holland JF: Mitoxantrone as single agent and combination chemotherapy in patients with refractory acute leukimia. Scmin Oncol 11(3SI): 36-40, 1984.
28. Lenk H, Muller U, Tanneberger S: Mitoxantrone: mechanism of action, antitumor activity, pharmacokinetics, efficacy in the treatment of solid tumors and lymphomas, and toxicity. Anticancer Res 7: 1257-1264, 1987.
29. Wei W, Nurse P, Broek D: Yeast cells can enter a quiescent state through G1, S, G2 or M phase of the cell cycle. Cancer Res 53: 1867-1870, 1993.
30. Van Belle SJP, de Planque MM, Smith IE, van Oosterom AT, Schoemaker TJ, Deneve W, McVie JG: Pharmacokinetics of mitoxantrone in humans following single-agent infusion or intraarterial injection therapy or combined-agent infusion therapy. Cancer Chemother Pharmacol 18: 27-32, 1986.